Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intracel Resources

Latest From Intracel Resources

Vaxon Biotech

Vaxon Biotech is developing therapeutic vaccines that stimulate the immune system to attack cancer cells without harming normal tissue, for a range of indications including prostate, lung, breast, hepatocellular, pancreatic and colon cancer. Based near Paris, Vaxon says it is the first company to develop therapeutic vaccines to treat existing cancers using optimized cryptic peptides, which appear to escape tolerance mechanisms, suggesting their potential in cancer immunotherapy.

Can Heat Shock Proteins Improve Immunotherapy?

Therapeutic vaccines derived from antigenic peptides have yet to demonstrate significant efficacy, particularly in cancer. Over the past eight years, a series of observations has led a small group of companies to believe that heat shock proteins possess unique properties that could make them useful adjuvants in vaccines designed to generate specific immune responses against cancers and infectious agents.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Intracel Corp.
  • Intracel Holdings Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intracel Resources
  • Senior Management
  • Mitchell Finer, PhD, CEO
  • Contact Info
  • Intracel Resources
    Phone: (301) 668-8300
    550 Highland St.
    Ste. 417
    Frederick, MD 21701